“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.
Copyright © 2024 | WordPress Theme by MH Themes